BrainStorm to Present Latest Company Developments at Regen Med Investor Day March 26 in New York

BrainStorm to Present Latest Company Developments at Regen Med Investor Day 
March 26 in New York 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 03/18/14
--  BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases,
announced today that Mr. Chen Schor, Executive Board Member, will
present the company's latest developments at the 2nd Annual Regen Med
Investor Day to be held Wednesday, March 26, 2014 in New York City. 
Organized by the Alliance for Regenerative Medicine (ARM) in
partnership with leading financial firms Maxim Group and Piper
Jaffray, this one-day investor conference focuses exclusively on the
regenerative medicine and advanced therapies sector. The event
includes clinical and commercial experts who will be on-hand to
address specific questions regarding the outlook for the industry, as
well as offer insight into how regenerative medicine products could
impact the standard of care in key therapeutic areas. The program
will include talks by key opinion leaders in the industry, life
science investment experts and analysts as well as presentations by
more than 30 leading companies from across the globe. 
The following are specific details regarding BrainStorm's
Event: ARM's Regen Med Investor Day 
Date: March 26, 2014 
Time: 4:00 pm 
Location: Metropolitan Club, One East 60th Street, New York, NY 10022 
A live-streaming webcast of all panels and company presentations will
be available at: and will be
published on the event's website shortly after the conference.  
Attendance at this event is for credentialed investors and members of
the media only. If you are interested in attending, please contact
Laura Parsons at Please visit for more information. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at  
About the Alliance for Regenerative Medicine
 The Alliance for
Regenerative Medicine (ARM) is a Washington, DC-based
multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate
access to life-giving advances in regenerative medicine and advanced
therapies. ARM also works to increase public understanding of the
field and its potential to transform human healthcare, providing
business development and investor outreach services to support the
growth of its member companies and research organizations. Prior to
the formation of ARM in 2009, there was no advocacy organization
operating in Washington, DC to specifically represent the interests
of the companies, research institutions, investors and patient groups
that comprise the entire regenerative medicine community. Today ARM
has more than 150 members and is the leading global advocacy
organization in this field. To learn more about ARM or to become a
member, visit  
Safe Harbor Statement
 Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI)
Mr. Chaim Lebovits
Phone: +972-3-9236384 
Press spacebar to pause and continue. Press esc to stop.